KRAS P.G12C
Clinical trials for KRAS P.G12C explained in plain language.
Never miss a new study
Get alerted when new KRAS P.G12C trials appear
Sign up with your email to follow new studies for KRAS P.G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough-to-treat pancreatic cancer patients with specific genetic mutation
Disease control Recruiting nowThis study is testing an experimental drug called Glecirasib for people with advanced pancreatic cancer and other solid tumors that have a specific genetic change called KRAS G12C. The trial is for patients whose cancer has continued to grow despite previous standard treatments. …
Matched conditions: KRAS P.G12C
Phase: PHASE2 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New pill targets 'Undruggable' cancer mutation in major trial
Disease control Recruiting nowThis early-stage trial is testing a new oral medication called D3S-001 for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find a safe dose, see how the body processes the drug, and get early signs of whether it helps …
Matched conditions: KRAS P.G12C
Phase: PHASE1, PHASE2 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC